PRESS RELEASE: MYOS CORP Announces Significant New Patent for Increasing Mobility and Activity in Dogs

Company’s eighth patent adds to robust IP Portfolio further establishing the unique efficacy of Fortetropin® in combating muscle loss.

CEDAR KNOLLS, N.J., December 12, 2023 /PRNewswire-PRWeb/ --

MYOS CORP, an innovation-driven medical nutrition company, announced today that it has been awarded US Patent No. 11,833,186, for its signature proprietary product, Fortetropin® - further cementing its science-backed claims to enhance mobility and activity in aging canines.


Fortetropin is the key ingredient in MYOS Canine Muscle Formula®, an all-natural dietary supplement that has been shown by eight published peer-reviewed clinical studies to have tremendous muscle health efficacy in mammals. The new patent, MYOS CORP’s eighth to date, specifically addresses the use of Fortetropin in treating canine muscle loss in conditions such as rheumatoid arthritis, osteoarthritis, and hip dysplasia, while also improving mobility and activity levels and reducing lean body mass wasting.


With this patent now in place, MYOS has an even clearer runway as a wholly-unique, all-natural, clinically proven supplement in the rapidly-growing and increasingly competitive animal health industry.


“MYOS stands out in protecting our innovative products with patents backed by clinically-validated, peer-reviewed studies,” said MYOS CORP CEO Joe Mannello. “We’re gratified that the US Patent Office continues to recognize the distinctiveness and effectiveness of Fortetropin, granting us robust patent protection.”


While numerous pet supplement brands claim an ability to enhance joint health as a way to combat the symptoms of aging, MYOS stands alone as the only company to offer a unique, clinically proven product to address muscle health. With eight published clinical studies and now eight U.S. patents, MYOS continues to build an impressive IP Portfolio that acts as a powerful separator from its competitors.


The global pet supplement market is experiencing rapid growth, reflecting a broader trend in pet care toward health and longevity. This expansion is particularly pronounced in the realm of senior dog care, where a growing number of products are being developed and marketed specifically for aging canines. This segment’s growth is fueled by pet owners’ increasing willingness to invest in their pets’ health, akin to how they care for human family members.



MYOS CORP is a Cedar Knolls, NJ based medical nutrition company that develops products that improve muscle health in people and animals. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass, and reduce muscle atrophy. MYOS products include MYOS Canine Muscle Formula®, MYOS Feline Muscle Formula®, MYOS Equine Muscle Formula®, and YOLKED®. For more information, please visit If you have any questions please contact

Back to blog